Holen Sie sich die Stockscreener-App
12.87
3.17%
-0.38
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - marketscreener.com
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation - TipRanks
IMMX Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.18 per Share, Shares Dip 3.38%Tax Rate Impact - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash - Stock Titan
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7%Here's What Happened - MarketBeat
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IMMX Q1 2026 Earnings: 15.25% EPS Surprise on Narrower Loss Despite No RevenueProfit Warning Alert - vinanet.vn
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday - MarketBeat
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law - Business Wire
Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immix Biopharma (IMMX) Advances 5.45% as Biotech Sentiment StrengthensBullish Sentiment - dars.gov.et
Immix Biopharma faces investigation after hirin... - Pluang
Immix Biopharma, Inc. expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Investing News Network
Immix Biopharma Announces Participation in Morgan Stanley 24th Annual Global Healthcare Conference and Institutional Investor Meetings - Quiver Quantitative
Janus Henderson Group PLC Boosts Stake in Immix Biopharma, Inc. $IMMX - MarketBeat
IMMX INVESTIGATION: Immix Biopharma Investors Who Lost Money After Reports About Its Former CMO Should Contact Block & Leviton - ACCESS Newswire
Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMMX|Immix Biopharma Inc|Price:8.690|Chg%:+0.170 - TradingKey
Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immix Biopharma Inc (IMMX) Cash Flow - TradingKey
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 9.7%What's Next? - MarketBeat
Immix Biopharma, Inc. Revenue Breakdown – NASDAQ:IMMX - TradingView
Immix Biopharma Inc (IMMX) Income Statement - TradingKey
Immix Biopharma Inc (IMMX) Balance Sheet - TradingKey
Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immix Biopharma Inc (IMMX) Institutional Confidence - TradingKey
Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMMX|Immix Biopharma Inc|Price:10.145|Chg%:+0.425 - TradingKey
IMMX|Immix Biopharma Inc|Price:13.940|Chg%:-0.370 - tradingkey.com
EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses - GlobeNewswire Inc.
Immix Biopharma, Inc. (IMMX) options chain - Yahoo Finance Australia
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):